https://medicine.yale.edu/lab/garg/news-rss/?title=News&orgId=124213 A selection of the latest research, academic, and other newsworthy developments at Garg Lupus Lab en-us Copyright 2026 Yale School of Medicine Fri, 14 Aug 2026 03:13:17 Z https://medicine.yale.edu/lab/garg/news-article/genetic-variants-kidney-transplant-rejection/ https://medicine.yale.edu/lab/garg/news-article/genetic-variants-kidney-transplant-rejection/ New research from Yale School of Medicine's Madhav Menon, MD, MBBS, identifies a potential genetic mechanism underlying the increased risk of kidney transplant rejection in some patients of recent African ancestry. Mon, 10 Aug 2026 12:48:00 Z https://medicine.yale.edu/lab/garg/news-article/womens-health-research-at-yale-and-swhrs-symposium-highlights-the-power-of-collaboration-to-advance-womens-health-research/ https://medicine.yale.edu/lab/garg/news-article/womens-health-research-at-yale-and-swhrs-symposium-highlights-the-power-of-collaboration-to-advance-womens-health-research/ This summer, we saw a first-of-its-kind cross-sector collaboration – a leader in academic research and a national women’s health nonprofit joined forces to amplify the power of women’s health research and investment. The collaborative symposium “From Discovery to Impact: Accelerating Women's Health Research Through Science, Policy, and Investment” hosted by Women’s Health Research at Yale and the Society for Women’s Health Research (SWHR) on June 15 in New Haven, Conn., welcomed more than 50 speakers, researchers from 28 departments across Yale, and gathered 350+ attendees for a day-long event that covered the power of women’s health research through an arc of discovery to practical impact. Tue, 30 Jun 2026 04:00:00 Z https://medicine.yale.edu/lab/garg/news-article/breaking-down-silos-to-understand-cardiometabolic-diseases/ https://medicine.yale.edu/lab/garg/news-article/breaking-down-silos-to-understand-cardiometabolic-diseases/ Meet Filipe Moura, MD, PhD, assistant professor of medicine (cardiovascular medicine), who recently received the Rising Star in Diabetes and Cardiorenal and Metabolic Medicine Award from The Metabolic Institute of America, which recognizes an early-career researcher for significant contributions to cardio-renal-metabolic medicine. Wed, 24 Jun 2026 04:00:00 Z https://medicine.yale.edu/lab/garg/news-article/putting-patients-at-the-center-of-lupus-research-and-care/ https://medicine.yale.edu/lab/garg/news-article/putting-patients-at-the-center-of-lupus-research-and-care/ Shivani Garg, MD, PhD, associate professor of medicine (rheumatology), director of the Lupus Clinical Research Program, and co‑director of the Yale Lupus Program, is dedicated to patient-centered lupus research and care. Thu, 07 May 2026 04:00:00 Z https://www.medpagetoday.com/reading-room/acrr/lupus/120970?xid=NL_ACRRR_2026-05-06&mh=&trw=no&zdee=&ptd=39&utm_source=Sailthru&utm_medium=email&utm_campaign=ACRReadingRoom_050626&utm_term=NL_Partner_ACR_Reading_Room_Active https://www.medpagetoday.com/reading-room/acrr/lupus/120970?xid=NL_ACRRR_2026-05-06&mh=&trw=no&zdee=&ptd=39&utm_source=Sailthru&utm_medium=email&utm_campaign=ACRReadingRoom_050626&utm_term=NL_Partner_ACR_Reading_Room_Active Study underscores the importance of starting early and continuing HCQ therapy to preserve kidney health Tue, 28 Apr 2026 04:00:00 Z https://www.medscape.com/viewarticle/hydroxychloroquine-blood-level-monitoring-can-enhance-2026a1000d8c https://www.medscape.com/viewarticle/hydroxychloroquine-blood-level-monitoring-can-enhance-2026a1000d8c Shivani Garg, MD, PhD, discusses emerging evidence that monitoring blood levels of hydroxychloroquine (HCQ) in patients with systemic lupus erythematosus may improve clinical care. This article highlights her recent work showing HCQ blood levels vary substantially among patients and that subtherapeutic levels are often associated with nonadherence or inadequate dosing, while excessively high levels raise safety concerns. Mon, 27 Apr 2026 04:00:00 Z https://www.medpagetoday.com/reading-room/acrr/lupus/120760?xid=NL_ACRRR_2026-04-29&mh=&trw=no&zdee=&ptd=39&utm_source=Sailthru&utm_medium=email&utm_campaign=ACRReadingRoom_042926&utm_term=NL_Partner_ACR_Reading_Room_Active https://www.medpagetoday.com/reading-room/acrr/lupus/120760?xid=NL_ACRRR_2026-04-29&mh=&trw=no&zdee=&ptd=39&utm_source=Sailthru&utm_medium=email&utm_campaign=ACRReadingRoom_042926&utm_term=NL_Partner_ACR_Reading_Room_Active Economic insecurities negatively affect patient-reported outcomes (PROs) in people with systemic lupus erythematosus (SLE). But social worker interventions can help improve PROs in this population. Tue, 14 Apr 2026 04:00:00 Z https://medicine.yale.edu/lab/garg/news-article/welcome-new-faculty-staff-postdocs-in-the-yale-department-of-internal-medicine-march-2026/ https://medicine.yale.edu/lab/garg/news-article/welcome-new-faculty-staff-postdocs-in-the-yale-department-of-internal-medicine-march-2026/ The Department of Internal Medicine welcomes the following new faculty, staff, postgraduate associates, and postdoctoral associates and fellows who joined the team in February 2026. Mon, 16 Mar 2026 04:00:00 Z https://www.medscape.com/viewarticle/obinutuzumab-lowers-nonrenal-lupus-disease-activity-phase-3-2026a10007lh?form=fpf https://www.medscape.com/viewarticle/obinutuzumab-lowers-nonrenal-lupus-disease-activity-phase-3-2026a10007lh?form=fpf In the phase 3 ALLEGORY trial (NEJM 2026; n=303), obinutuzumab added to standard care significantly improved active non-renal SLE vs placebo. The primary endpoint, SRI-4 response at 52 weeks, was 76.7% vs 53.5%, and all key secondary endpoints favored obinutuzumab: BICLA (62.0% vs 40.1%), steroid taper to ≤7.5 mg/d (80.0% vs 54.1%), reduced BILAG flare risk (HR 0.58), remission (35.1% vs 13.8%), and LLDAS (57.6% vs 25.0%). Safety was comparable. Dr. Shivani Garg was quoted in the article calling it a strong study and good option for extrarenal lupus, noting that organ-specific and head-to-head data are still needed. Thu, 12 Mar 2026 04:00:00 Z https://www.medscape.com/viewarticle/time-monitor-serum-hydroxychloroquine-levels-systemic-lupus-2025a1000fvl?form=fpf https://www.medscape.com/viewarticle/time-monitor-serum-hydroxychloroquine-levels-systemic-lupus-2025a1000fvl?form=fpf Shivani Garg, MD, PhD, presented the findings of an observational study that confirmed and extended the results from an earlier study carried out by her research group that the ideal blood hydroxychloroquine level lay somewhere between a lower limit of 750 ng/mL and an upper limit of 1150 ng/mL for most patients with SLE. Fri, 13 Jun 2025 04:00:00 Z